Kymera Therapeutics, Inc. (KYMR) 8-K Current Report: February 26, 2026
Filed: February 26, 2026
Health Care
Biological Products, (No Diagnostic Substances)Kymera Therapeutics, Inc. (KYMR) 8-K current report filed with SEC EDGAR on February 26, 2026. This page provides AI-powered analysis of reported events and material disclosures, including results of operations, corporate governance changes, agreements, and other triggering events as disclosed under Form 8-K item codes.
Reported 8-K Items3 items
- Item 1.01: Entry into a Material Definitive Agreement
- Item 1.02: Termination of a Material Definitive Agreement
- Item 8.01: Other Events
Kymera Therapeutics, Inc. 8-K Feb 26, 2026 Event Analysis
Item 1.01 · Entry into a Material Definitive Agreement
- • ATM equity offering up to $500M via TD Cowen, sold opportunistically on Nasdaq at Company's discretion
- • TD Cowen earns up to 3.0% commission on gross proceeds — no obligation to sell any minimum amount
- • Potential dilution risk: $500M in new shares could be issued at any time without further shareholder approval
- • Shelf registration (Form S-3ASR filed Oct 2024) already effective, enabling rapid capital deployment with no additional SEC review delay
Item 1.02 · Termination of a Material Definitive Agreement
- • ATM equity offering program with Jefferies terminated immediately effective February 26, 2026
- • Removal of at-the-money sales channel signals company may no longer need opportunistic equity raises via open market
- • Investors should watch for alternative financing announcements or indication current cash runway is sufficient without ATM dilution
Item 8.01 · Other Events
- • Resale registration covers up to 18.8M common shares + 12.6M pre-funded warrant shares (~31.4M total shares eligible for market sale
- • Selling stockholders: Baker Brothers, 667 L.P., Atlas Venture, BVF Partners — all institutional insiders from June 2025 registration rights agreement
- • Company receives no proceeds from share resales; minimal proceeds only if warrants exercised for cash at $0.0001/share
- • Registration ≠ immediate sale — but unlocks significant potential supply overhang (~31.4M shares) that could pressure stock price
- • No new dilution to existing shareholders; these are already-issued shares being registered for resale
Other Kymera Therapeutics, Inc. 8-K Filings
Get deeper insights on Kymera Therapeutics, Inc.
Access full AI analysis, insider trading data, fund holdings, and cross-signal detection on SignalX.